Payment overview · 2025
General Payments
$795.29
38 reported records · 10 companies
Healthcare provider profile · identity verified
Jonathan Lyons, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MC DOWELL, KY · NPI 1104213206
Verified facts
What the public records show
CMS Open Payments records show Jonathan Lyons, D.O. received $795.29 in general payments during 2025 across 38 reported records.
Novartis Pharmaceuticals Corporation accounted for 34.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $270.41 | 34.0% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $230.56 | 29.0% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $103.22 | 13.0% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.15 | 4.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.10 | 4.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.28 | 3.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.98 | 3.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.14 | 2.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.26 | 2.7% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.19 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $795.29 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $270.41 | 16 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $172.89 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $109.25 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $103.22 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $75.62 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $44.14 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.10 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.28 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.98 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 53 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 354 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 264 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 257 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 206 | 45 |
| Lisinopril | Lisinopril | 194 | 47 |
| Metformin Hcl | Metformin Hcl | 164 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 161 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 154 | 37 |
| Omeprazole | Omeprazole | 144 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 143 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 124 | 31 |
| Diazepam | Diazepam | 117 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 29 |
| Meloxicam | Meloxicam | 111 | 29 |
| Furosemide | Furosemide | 109 | 34 |
| Montelukast Sodium | Montelukast Sodium | 103 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 98 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 93 | 13 |
| Losartan Potassium | Losartan Potassium | 89 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 18 |
| Potassium Chloride | Potassium Chloride | 87 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 85 | 15 |
| Ozempic | Semaglutide | 80 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 16 |
| Carvedilol | Carvedilol | 67 | 15 |
| Alprazolam | Alprazolam | 66 | 11 |
| Glipizide | Glipizide | 63 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 62 | 17 |
| Trazodone Hcl | Trazodone Hcl | 61 | 15 |
| Celecoxib | Celecoxib | 59 | 16 |
| Mounjaro | Tirzepatide | 59 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 16 |
| Prednisone | Prednisone | 55 | 29 |
| Famotidine | Famotidine | 53 | 11 |
| Farxiga | Dapagliflozin Propanediol | 53 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | suppressed |
| Eliquis | Apixaban | 52 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 52 | 11 |
| Promethazine Hcl | Promethazine Hcl | 50 | 12 |
| Buspirone Hcl | Buspirone Hcl | 49 | suppressed |
| Fenofibrate | Fenofibrate | 49 | suppressed |
| Allopurinol | Allopurinol | 48 | 12 |
| Ibuprofen | Ibuprofen | 48 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 17 |
| Pregabalin | Pregabalin | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 32 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | 13 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Nystatin | Nystatin | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Azithromycin | Azithromycin | 28 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 18 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Simvastatin | Simvastatin | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $795.29 · 38 records | Novartis Pharmaceuticals Corporation | AIRSUPRA, BREZTRI, CAPLYTA, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, JARDIANCE, Kerendia, LEQVIO, QULIPTA, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, TRELEGY ELLIPTA, UBRELVY, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error